Best confirmed response rates and time-to-event outcomes with SC and IV bortezomib (± dexamethasone) according to renal subgroup (CrCl 20–50 or >50 mL/min), in response-evaluable patients (those with measurable, secretory multiple myeloma who received ≥1 dose of bortezomib; response rates and time to response) or the intent-to-treat population (other outcomes).